Please login to the form below

Not currently logged in
Email:
Password:

Corlaner

This page shows the latest Corlaner news and features for those working in and with pharma, biotech and healthcare.

Amgen takes aim at cardio diseases with Arrowhead RNAi deal

Amgen takes aim at cardio diseases with Arrowhead RNAi deal

Amgen is a recent entrant into the cardiovascular drugs arena, with recently-approved cholesterol-lowering drug Repatha (evolocumab) and heart failure drug Corlaner (ivabradine) spearheading its assault on the market.

Latest news

  • Amgen starts shipping Corlaner in US Amgen starts shipping Corlaner in US

    Amgen starts shipping Corlaner in US. Firm also reports healthy financial growth in the first quarter. ... Amgen has started shipping its Corlaner heart failure therapy to wholesalers in the US just a few days after getting FDA approval for the drug.

  • FDA clears Amgen's Corlaner for heart failure FDA clears Amgen's Corlaner for heart failure

    FDA clears Amgen's Corlaner for heart failure. It is the firm’ s first cardiovascular product to gain approval. ... Amgen's heart failure drug Corlaner has been given the green light by the US FDA, giving the company its first approved cardiovascular

  • Amgen banking on three launches in 2015 Amgen banking on three launches in 2015

    year. These are evolocumab for high cholesterol, heart failure drug Corlaner (ivabradine) and talimogene laherparepvec (T-VEC) for melanoma. ... Despite the upbeat comments, Amgen did reveal that Corlaner and T-VEC have both been delayed by requests for

  • Amgen gets priority review for chronic heart failure hope Amgen gets priority review for chronic heart failure hope

    Raises expectations for early entry onto US market for ivabradine

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    Corlaner costs around the same as Entresto at around $4, 500 per year. ... Entresto and Corlaner are expected to account for the bulk of that increase, with Entresto taking the lion's share.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics